S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.90 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.90 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.90 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.90 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
NASDAQ:TRVN

Trevena (TRVN) Stock Forecast, Price & News

$0.65
+0.01 (+1.70%)
(As of 01:45 PM ET)
Compare
Today's Range
$0.65
$0.66
50-Day Range
$0.64
$1.02
52-Week Range
$0.54
$5.13
Volume
9,877 shs
Average Volume
1.23 million shs
Market Capitalization
$8.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Trevena MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
751.4% Upside
$5.50 Price Target
Short Interest
Bearish
8.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Trevena in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.10) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars


TRVN stock logo

About Trevena (NASDAQ:TRVN) Stock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

TRVN Price History

TRVN Stock News Headlines

Trevena (NASDAQ: TRVN)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Trevena Shares Rise 18% After Getting $15M Tranche
Biotech Shares Are Running Again!
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
JMP Securities Remains a Buy on Trevena (TRVN)
TRVN - Trevena, Inc.
Trevena Achieves Listing Compliance On Nasdaq
JMP Securities Sticks to Their Buy Rating for Trevena (TRVN)
Trevena Earnings Preview
Trevena Q1 Earnings Preview
See More Headlines
Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVN
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+743.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,670,000.00
Pretax Margin
-1,461.22%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$2.25 per share

Miscellaneous

Free Float
13,260,000
Market Cap
$8.94 million
Optionable
Optionable
Beta
1.91
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Ms. Carrie L. BourdowMs. Carrie L. Bourdow (Age 60)
    Pres, CEO & Director
    Comp: $1M
  • Mr. Barry Shin (Age 51)
    Sr. VP & CFO
    Comp: $670.02k
  • Dr. Mark A. Demitrack (Age 65)
    Sr. VP & Chief Medical Officer
    Comp: $690.32k
  • Dr. Howard A. Rockman M.D.
    Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Joel Solomon
    VP, Gen. Counsel & Chief Compliance Officer
  • Mr. Michael Catalano
    VP of Marketing
  • Mr. Robert T. Yoder (Age 57)
    Sr. VP, Chief Bus. Officer & Head of Commercial Operations
  • Ms. Patricia M. Drake (Age 57)
    Sr. VP & Chief Commercial Officer













TRVN Stock - Frequently Asked Questions

Should I buy or sell Trevena stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings
or view top-rated stocks.

What is Trevena's stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price objectives for Trevena's stock. Their TRVN share price forecasts range from $2.00 to $9.00. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 743.3% from the stock's current price.
View analysts price targets for TRVN
or view top-rated stocks among Wall Street analysts.

How have TRVN shares performed in 2023?

Trevena's stock was trading at $1.43 at the beginning of 2023. Since then, TRVN stock has decreased by 54.4% and is now trading at $0.6522.
View the best growth stocks for 2023 here
.

Are investors shorting Trevena?

Trevena saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,130,000 shares, an increase of 207.5% from the August 31st total of 367,500 shares. Based on an average daily volume of 615,800 shares, the short-interest ratio is currently 1.8 days. Approximately 8.4% of the shares of the stock are sold short.
View Trevena's Short Interest
.

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our TRVN earnings forecast
.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.24. The biopharmaceutical company had revenue of $3.02 million for the quarter, compared to analysts' expectations of $0.70 million.

When did Trevena's stock split?

Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?
What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.66%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends
.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.65.

How much money does Trevena make?

Trevena (NASDAQ:TRVN) has a market capitalization of $8.94 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-53,670,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.

This page (NASDAQ:TRVN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -